Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy

Saudi Journal of Gastroenterology

Volumn 18, Issue 2, 2012, Pages 118-121

  Fischer, Richard ^b   Breidert, Matthias ^a   Keck, Tobias ^b   Makowiec, Frank ^b   Lohrmann, Christian ^b   Harder, Jan ^c  

^a Abteilung Diabetes und Fussambulanz   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Hegau Bodensee Klinikum   (Germany)

Author keywords

Adjuvant chemotherapy; pancreatic cancer; recurrence

Indexed keywords

GEMCITABINE;

ADJUVANT THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DISTANT METASTASIS; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; RISK FACTORS; TIME FACTORS;

EID: 84858984695     PISSN: 13193767     EISSN: 19984049     Source Type: Journal    
DOI: 10.4103/1319-3767.93815     Document Type: Article

References (29)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010;60:277-300.
2. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999;230:776-82; discussion 782-4.
3. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267-77. (Pubitemid 46143304)
4. Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503-10.
5. Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009;100:246-50
6. Neuhaus P, Riess H, Post S, Gellert K, Ridwelski K, Schramm H, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer. J Clin Oncol 2008;26:abstr. LBA4504.
7. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomized phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese study group of adjuvant therapy of pancreatic cancer. Br J Cancer 2009;101:908-15.
8. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, et al. Fluorouracil vs. gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008;299:1019-26. (Pubitemid 351347058)
9. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10. (Pubitemid 38339364)
10. Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: A randomized controlled trial. JAMA 2010;304:1073-81.
11. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G, et al. S3-Guidelines "Exocrine pancreatic cancer" 2007. Z Gastroenterol 2007;45:487-523. (Pubitemid 47056016)
12. Heinemann V, Boeck S. Perioperative management of pancreatic cancer. Ann Oncol 2008;19 Suppl 7:vii273-8
13. Xie DR, Yang Q, Chen DL, Jiang ZM, Bi ZF, Ma W, et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: Updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 2010;40:432-41.
14. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6. (Pubitemid 46972777)
15. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25.
16. Brus C, Saif MW. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010;11:321-3.
17. Petrelli F, Borgonovo K, Ghilardi M, Cabiddu M, Barni S. What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies. Rev Recent Clin Trials 2010;5:43-56.
18. Pliarchopoulou K, Pectasides D. Pancreatic cancer: Current and future treatment strategies. Cancer Treat Rev 2009;35:431-6.
19. Vanderveen KA, Chen SL, Yin D, Cress RD, Bold RJ. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer 2009;115:2420-9.
20. Mayo SC, Austin DF, Sheppard BC, Mori M, Shipley DK, Billingsley KG. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer 2010;116:2932-40.
21. Cascinu S, Falconi M, Valentini V, Jelic S. Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21 Suppl 5:v55-8.
22. Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, et al. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017.
23. Berger AC, Garcia M Jr, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008;26:5918-22.
24. Boeck S, Bruns CJ, Sargent M, Schafer C, Seufferlein T, Jauch KW, et al. Current oncological treatment of patients with pancreatic cancer in Germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Oncology 2009;77:40-8.
25. Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group. Eur J Cancer 2011;47:1676-81.
26. Merl MY, Abdelghany O, Li J, Saif MW. First-line treatment of metastatic pancreatic adenocarcinoma: Can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010. JOP 2010;11:317-20.
27. Tamahashi U, Kumagai J, Takizawa T, Sekine M, Eishi Y. Expression and intracellular localization of matrix metalloproteinases in intraductal papillary mucinous neoplasms of the pancreas. Virchows Arch 2008;453:79-87.
28. Kurata N, Fujita H, Ohuchida K, Mizumoto K, Mahawithitwong P, Sakai H, et al. Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil. Int J Oncol 2011;39:473-82.
29. Maithel SK, Coban I, Kneuertz PJ, Kooby DA, El-Rayes BF, Kauh JS, et al. Differential expression of ERCC1 in pancreas adenocarcinoma: High tumor expression is associated with earlier recurrence and shortened survival after resection. Ann Surg Oncol 2011;18:2699-705.